INFECTIOUS INNOVATION

We led the development of molnupiravir, the world’s first oral direct acting antiviral drug for COVID-19 (A), through IND filing. Interim Phase 3 data showed molnupiravir reduced hospitalization by 50% in mild to moderate COVID-19 patients with at least one risk factor and reduced deaths to zero in that same patient group. See NEWS for latest updates and approvals.
We led the development of molnupiravir, the world’s first oral direct acting antiviral drug for COVID-19 (A), through IND filing. Interim Phase 3 data showed molnupiravir reduced hospitalization by 50% in mild to moderate COVID-19 patients with at least one risk factor and reduced deaths to zero in that same patient group. See NEWS for latest updates and approvals.
We led the development of molnupiravir, the world’s first oral direct acting antiviral drug for COVID-19 (A), through IND filing. Interim Phase 3 data showed molnupiravir reduced hospitalization by 50% in mild to moderate COVID-19 patients with at least one risk factor and reduced deaths to zero in that same patient group. See NEWS for latest updates and approvals.

In addition to molnupiravir, DRIVE’s Leadership has discovered and advanced the development of some of the world’s most successful and valuable antiviral drugs. DRIVE combines these seasoned leaders with over $20M in foundational funding from Emory University to build a world class infrastructure for developing drugs for viral diseases of global concern. We invite you to join with us in our urgent quest to develop valuable and critically needed drugs to fight against these viral threats.

Learn More

Team

DRIVE’s leadership team has extensive experience in the biotechnology and pharmaceutical industries with proven track records in discovering and advancing some of the world’s most successful and valuable antiviral drugs.

Read More

Collaborations

We are seeking strategic industry, academic, and government collaborators to provide exciting new discoveries, financing, and late stage commercial development in order to move more therapeutics from bench to patient.

Read More

News

DRIVE is off to a fast start. Track our progress.

Read More

For more information, contact: [email protected]

©2013 DRIVE